August 2012
-
A study of COPD patients by researchers from Johhs Hopkins found that use of inhaled corticosteroids for six months increased the risk of bone fracture by 27%. The researchers reviewed data from both double-blind and… Read more . . .
-
An intranasal formulation of diazepam being developed by Neurelis for the treatment of acute seizures outside of a hospital setting demonstrated 96% bioavailability compared to the only currently approved treatment, a rectal diazepam gel. The… Read more . . .
-
The Pulmonary & Nasal laboratory Scientist team at Catalent is responsible for the support of pharmaceutical product development in a range of dosage forms both directly with customers and in collaboration with other Catalent facilities.… Read more . . .
-
Massacheusetts biotech company is introducing a new dry powder delivery platform based on its iSPERSE cationic salt formulations at ISAM 2011. According to the company, the iSPERSE platform “enables inhaled delivery of high drug loads,… Read more . . .
-
In an effort to continue their leading status of innovation and development, through Four Corners Group, Trudell Medical International is now seeking a Group Director, Science & Technology. THE ROLE This position will be responsible… Read more . . .
-
A Phase 2b study of Aradigm’s inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchietasis has shown a significant reduction in Pseudomonas aeruginosa colony forming units per gram of sputum (CFUs) over a 28-day treatment… Read more . . .
-
Pearl Therapeutics is advancing its PT003 combination inhaler for COPD, and the products individual components, into a new series of Phase 2 trials in patients with moderate-to-severe COPD. The individual compounds are PT001, glycopyrrolate, and… Read more . . .
-
Lamellar Biomedical’s LMS-611, an inhaled Lamellasome, an artificial lamellar body, for the treatment of patients with cystic fibrosis has received orphan drug designation from the European Commission. CF patients’ lungs may be missing lamellar bodies… Read more . . .
-
The “Deep Draw Container Forming Method” developed by Mystic Pharmaceuticals for packaging of intranasal drugs for use with its VersiDoser and VRx2 intranasal delivery systems has been awarded US Patent No. 7,963,089. Both delivery systems… Read more . . .
-
After receiving written guidance from the FDA in late May, says Generex, it has revised its development program for its Oral-lyn buccal insulin spray. A reorganized medical/regulatory group within the company will focus its efforts… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.